Stock NMRA NEUMORA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
11.05 USD -4.33% Intraday chart for Neumora Therapeutics, Inc. +7.80% -35.19%
Jul. 08 Mizuho Securities Initiates Neumora Therapeutics at Outperform With $20 Price Target MT
Jul. 01 Neumora Therapeutics, Inc.(NasdaqGS:NMRA) dropped from Russell Small Cap Comp Value Index CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mizuho Securities Initiates Neumora Therapeutics at Outperform With $20 Price Target
MT
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) dropped from Russell Small Cap Comp Value Index
CI
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) dropped from Russell 3000 Value Index
CI
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) dropped from Russell 2500 Value Index
CI
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) dropped from Russell 2000 Value Index
CI
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) dropped from Russell 3000E Value Index
CI
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
AQ
Neumora Therapeutics, Inc. Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer?s Disease Agitation
CI
Transcript : Neumora Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 09:00 AM
Transcript : Neumora Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression
MT
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
AQ
Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
CI
Neumora Therapeutics Shares Fall as Q1 Loss Narrows
MT
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Neumora Therapeutics to Participate in Upcoming Conferences in May
AQ
Sector Update: Health Care Stocks Advance Premarket Monday
MT
Sector Update: Health Care
MT
Investors Shrug Off Geopolitical Concerns, Driving Premarket Gains for US Equity Futures
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NMRA Stock
  4. News Neumora Therapeutics, Inc.